Invention Grant
- Patent Title: Anticancer agent comprising HVJ-E and immune checkpoint protein inhibitor
-
Application No.: US16346576Application Date: 2017-11-01
-
Publication No.: US11166995B2Publication Date: 2021-11-09
- Inventor: Yasufumi Kaneda , Kazuma Sakura , Tomoyuki Nishikawa , Masanori Fukushima , Toshihiro Nakajima
- Applicant: OSAKA UNIVERSITY , GENOMIDEA INC.
- Applicant Address: JP Suita; JP Osaka
- Assignee: OSAKA UNIVERSITY,GENOMIDEA INC.
- Current Assignee: OSAKA UNIVERSITY,GENOMIDEA INC.
- Current Assignee Address: JP Suita; JP Osaka
- Agency: Leydig, Voit & Mayer, Ltd.
- Priority: JPJP2016-214198 20161101
- International Application: PCT/JP2017/039568 WO 20171101
- International Announcement: WO2018/084185 WO 20180511
- Main IPC: A61K35/76
- IPC: A61K35/76 ; A61P35/00 ; C12N7/00 ; A61K39/395 ; A61K31/7105 ; A61K45/00 ; A61P43/00 ; A61K31/711 ; A61P35/02 ; A61P37/04
Abstract:
The present invention provides an anticancer agent containing the following (1) and (2):
(1) HVJ-E (hemagglutinating virus of Japan envelope),
(2) an inhibitor of an immune checkpoint protein.
(1) HVJ-E (hemagglutinating virus of Japan envelope),
(2) an inhibitor of an immune checkpoint protein.
Public/Granted literature
- US20190275091A1 ANTICANCER AGENT COMPRISING HVJ-E AND IMMUNE CHECKPOINT PROTEIN INHIBITOR Public/Granted day:2019-09-12
Information query
